KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103. A total of 69 filers reported holding KALVISTA PHARMACEUTICALS INC in Q1 2019. The put-call ratio across all filers is - and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $496,176 | +299.0% | 51,524 | +180.1% | 0.00% | – |
| Q4 2022 | $124,357 | -90.6% | 18,396 | -86.2% | 0.00% | -100.0% |
| Q2 2022 | $1,316,000 | +145.5% | 133,687 | +267.7% | 0.00% | +200.0% |
| Q1 2022 | $536,000 | +31.7% | 36,359 | +113.9% | 0.00% | -50.0% |
| Q2 2021 | $407,000 | -57.7% | 16,996 | -54.6% | 0.00% | -50.0% |
| Q1 2021 | $962,000 | +582.3% | 37,443 | +102.9% | 0.00% | +300.0% |
| Q1 2020 | $141,000 | -91.6% | 18,454 | -68.7% | 0.00% | -87.5% |
| Q1 2019 | $1,686,000 | – | 58,904 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Stonepine Capital Management, LLC | 422,310 | $10,849,000 | 5.86% |
| COMMODORE CAPITAL LP | 214,467 | $5,510,000 | 2.20% |
| Vivo Capital, LLC | 1,863,296 | $47,868,000 | 1.68% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 214,533 | $5,486,000 | 1.45% |
| Nicholas Investment Partners, LP | 594,130 | $15,263,000 | 1.06% |
| Altium Capital Management LP | 128,130 | $3,292,000 | 0.91% |
| Affinity Asset Advisors, LLC | 100,000 | $2,569,000 | 0.87% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 50,000 | $1,285,000 | 0.70% |
| APIS CAPITAL ADVISORS, LLC | 30,000 | $771,000 | 0.70% |
| Birchview Capital, LP | 40,000 | $1,028,000 | 0.61% |